Can a new drug combo shrink liver tumors in Hard-to-Treat colorectal cancer?
Disease control
Not yet recruiting
This phase II trial tests whether adding retlirafusp alfa to standard chemotherapy and bevacizumab can shrink tumors in people with advanced RAS-mutated colorectal cancer that has spread to the liver. The study enrolls 46 adults who have not had prior systemic treatment and whose…
Phase 2 • Sponsor: Dai, Guanghai • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC